Ramucirumab 500mg (Ramucirumab)

Contact us for more information
Wishlist Compare
Brand nameCyramzaInternational trade nameCyramzaActive substanceRamucirumabStrength500mgCategoryAnti Cancer

Description of Cyramza 500mg (Ramucirumab 500mg)

Cyramza 500mg (Ramucirumab 500mg) belongs to Intravenous human monoclonal antibody which prohibits VEGFR2and it increased the haemorrhage risk which may be serious and sometimes fatal. Stop if severe bleeding occurs.

Cyramza 500mg (Ramucirumab 500mg) is a prescription medicines which is used under supervision of doctor

Medical use /Indication of Cyramza 500mg (Ramucirumab 500mg)

Cyramza 500mg (Ramucirumab 500mg) injection indicated for;

  • As a single agent, or in concomitant use with paclitaxel for the treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
  • In concomitant use with docetaxel for the treatment for metastatic non-small cell lung cancer
  • In concomitant use with FOLFIRI for the treatment of patients with metastatic colorectal cancer

Mechanism of Action Cyramza 500mg (Ramucirumab 500mg)

Ramucirumab belongs to vascular endothelial growth factor receptor 2 antagonist which efficiently binds VEGF Receptor 2 and stops binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D.
As a result, ramucirumab prohibits ligand-stimulated activation of VEGF Receptor 2, thereby prohibiting ligand-induced multiplication, and migration of human endothelial cells.
Ramucirumab prevented angiogenesis in an in vivo animal model.
Half-life of ramucirumab 14 days

Side effects of Cyramza 500mg (Ramucirumab 500mg)

  • Fatigue/asthenia
  • Neutropenia
  • Diarrhea
  • Epistaxis
  • Peripheral edema
  • Stomatitis
  • Proteinuria
  • Hypertension
  • Infusion-related reactions
  • Hypertension grade 3-4
  • Thrombocytopenia
  • Hypoalbuminemia .

Precautions of Cyramza 500mg (Ramucirumab 500mg)

Increased the risk of haemorrhage and gastrointestinal haemorrhage, containing severe and sometimes fatal haemorrhagic events enduringly discontinue patients who experience severe bleeding

The medicine may have high the risk of gastrointestinal perforation, a probably fatal event

Completely stop in patients who experience a gastrointestinal perforation

Impaired wound healing can appear with antibodies prohibiting the VEGF pathway

Avoid in patients with impaired wound healing

Hold up medicine prior to surgery and discontinue if a patient occurs wound healing complications

Drug interaction of Cyramza 500mg (Ramucirumab 500mg)

Cyramza 500mg (Ramucirumab 500mg) has No clinically meaningful difference in the exposure of either ramucirumab or its combination medicines in the approved combinations, contains paclitaxel, docetaxel, and irinotecan were observed in patients with solid tumor

Pregnancy of Cyramza 500mg (Ramucirumab 500mg)

Pregnancy, lactation, pediatric:

Based on mechanism ramucirumab will cause fetal harm. Cyramza 500mg (Ramucirumab 500mg) has no available data while use in pregnant women to inform any medicine –associated risks.

Lactation of Cyramza 500mg (Ramucirumab 500mg)

Excretion into human milk is unknown. Avoid the Cyramza 500mg (Ramucirumab 500mg) during treatment.

Dosage of Cyramza 500mg (Ramucirumab 500mg)

Non-Small Cell Lung Cancer :

The usual dose is 10 mg/kg IV infused over ~1 hr prior to docetaxel (75 mg/m²) IV infusion on Day 1 of a 21-day cycle. Continue until disease progression or unacceptable toxicity

Gastric Cancer:

As a monotherapy agent or in co administration with paclitaxel is used.

Usual dose for Single agent or in combination with paclitaxel is 8 mg/kg IV q2wk; infuse over 1 hr

Usual dose for Paclitaxel (if given in combination) is 80 mg/m² once weekly for 3 weeks of every 28-day cycle.

When given in concomitant, administer ramucirumab prior to administration of paclitaxel. Follow until disease progression or unacceptable toxicity

Colorectal Cancer:

In combination with FOLFIRI for the treatment

Usual dose is 8 mg/kg IV q2wk; administer by IV infusion over 60 minutes prior to FOLFIRI administration. Follow until disease progression or unacceptable toxicity

Storage of Cyramza 500mg (Ramucirumab 500mg)

Store the vial at 2℃ to 8℃ Discard product if it contains particulate matter, is cloudy, or discoloured Dispose unused portion. Do not store for later use.

Missed dose of Cyramza 500mg (Ramucirumab 500mg)

Take the dose immediately before next dose duration, Next dose time reaches then left off the missed dose and continue regular schedule. Avoid taking double dose at same time. Please consult the doctor for further information.

Brand name:
International trade name:
Active substance:
Anti Cancer
1 Vial
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India